NCT04542330View on ClinicalTrials.gov

Using BCG to Protect Senior Citizens During the COVID-19 Pandemic

PHASE3CompletedINTERVENTIONAL
Enrollment

1,700

Participants

Timeline

Start Date

September 15, 2020

Primary Completion Date

January 11, 2023

Study Completion Date

January 11, 2023

Conditions
Covid19Non-specific Effects of VaccinesHeterologous ImmunityMorbidityImmunosenescenceVaccine Preventable Disease
Interventions
BIOLOGICAL

BCG-Denmark

Mycobacterium bovis BCG live attenuated BCG-Denmark vaccine (AJ Vaccines, Copenhagen, Denmark) administered by intradermal injection in the left deltoid region.

BIOLOGICAL

Saline

Participants randomized to the control group will receive one 0.1 ml dose sterile 0.9 % NaCl by intradermal injection in the left deltoid region.

Trial Locations (1)

5000

Seniorhuset, Odense

All Listed Sponsors
collaborator

Odense Patient Data Explorative Network

OTHER

collaborator

Odense University Hospital

OTHER

collaborator

Municipality of Odense

OTHER_GOV

lead

Bandim Health Project

OTHER

NCT04542330 - Using BCG to Protect Senior Citizens During the COVID-19 Pandemic | Biotech Hunter | Biotech Hunter